Faecal calprotectin as a marker for oesophago-gastric cancer
Authors:
Open Access
- 2 March 2015
- journal article
- research article
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 52 (6) , 660-664
Abstract
Background: Faecal calprotectin has been shown to be useful as a non-invasive screening test to differentiate functional from organic bowel disease, and it has been noted to be elevated in colorectal cancer. The aim of this study was to describe concentrations of faecal calprotectin in patients with oesophago-gastric cancer and investigate any potential discriminatory power of the test. Patients: Faecal calprotectin was measured in samples from 39 patients with known oesophago-gastric cancer and in 191 samples from control subjects. Results: The median calprotectin concentration was < 20 µg/g (range < 20–421 µg/g) in control subjects and 97 µg/g (range < 20–940 µg/g) in patients with oesophago-gastric cancer (P < 0.001). A receiver operating characteristic curve gave an area under the ROC curve of 0.84 and a sensitivity of 76.9% (95% CI: 63.7–90.1%) and specificity of 88.0% (95% CI: 83.3–92.6%) at a cutoff of 50 µg/g. Conclusion: Faecal calprotectin is elevated in patients with cancer of the upper gastrointestinal tract. This study suggests that calprotectin may be promising in discriminating cancer patients from controls, but further work is required to explore any potential role of faecal calprotectin in screening for, or diagnosis of, oesophago-gastric cancer.Keywords
This publication has 17 references indexed in Scilit:
- Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysisBMJ, 2010
- Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteersAnnals of Clinical Biochemistry: International Journal of Laboratory Medicine, 2009
- Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel diseaseDigestive and Liver Disease, 2009
- Diagnostic Precision of Fecal Calprotectin for Inflammatory Bowel Disease and Colorectal MalignancyAmerican Journal of Gastroenterology, 2007
- Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT)Gut, 2004
- Calprotectin (S100A8/S100A9), an Inflammatory Protein Complex from Neutrophils with a Broad Apoptosis-Inducing ActivityBiological and Pharmaceutical Bulletin, 2003
- Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenomaGut, 2001
- Faecal calprotectin levels in a high risk population for colorectal neoplasiaGut, 2000
- Intestinal permeability: An overviewGastroenterology, 1995
- False positive localisation of indium-111 granulocytes in colonic carcinomaBritish Journal of Radiology, 1986